<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Dermatol</journal-id><journal-id journal-id-type="iso-abbrev">J. Dermatol</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1346-8138</journal-id><journal-id journal-id-type="publisher-id">JDE</journal-id><journal-title-group><journal-title>The Journal of Dermatology</journal-title></journal-title-group><issn pub-type="ppub">0385-2407</issn><issn pub-type="epub">1346-8138</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28714180</article-id><article-id pub-id-type="pmc">5697670</article-id><article-id pub-id-type="doi">10.1111/1346-8138.13956</article-id><article-id pub-id-type="publisher-id">JDE13956</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Articles</subject></subj-group></article-categories><title-group><article-title>Tofacitinib for the treatment of moderate to severe chronic plaque psoriasis in Japanese patients: Subgroup analyses from a randomized, placebo&#x02010;controlled phase 3 trial</article-title><alt-title alt-title-type="left-running-head">M. Abe <italic>et al</italic>.</alt-title></title-group><contrib-group><contrib id="jde13956-cr-0001" contrib-type="author" corresp="yes"><name><surname>Abe</surname><given-names>Masatoshi</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-8863-9428</contrib-id><address><email>masaabe@kojinkai.org</email></address><xref ref-type="aff" rid="jde13956-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jde13956-cr-0002" contrib-type="author"><name><surname>Nishigori</surname><given-names>Chikako</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6784-2849</contrib-id><xref ref-type="aff" rid="jde13956-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="jde13956-cr-0003" contrib-type="author"><name><surname>Torii</surname><given-names>Hideshi</given-names></name><xref ref-type="aff" rid="jde13956-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="jde13956-cr-0004" contrib-type="author"><name><surname>Ihn</surname><given-names>Hironobu</given-names></name><xref ref-type="aff" rid="jde13956-aff-0004">
<sup>4</sup>
</xref></contrib><contrib id="jde13956-cr-0005" contrib-type="author"><name><surname>Ito</surname><given-names>Kei</given-names></name><xref ref-type="aff" rid="jde13956-aff-0005">
<sup>5</sup>
</xref></contrib><contrib id="jde13956-cr-0006" contrib-type="author"><name><surname>Nagaoka</surname><given-names>Makoto</given-names></name><xref ref-type="aff" rid="jde13956-aff-0006">
<sup>6</sup>
</xref></contrib><contrib id="jde13956-cr-0007" contrib-type="author"><name><surname>Isogawa</surname><given-names>Naoki</given-names></name><xref ref-type="aff" rid="jde13956-aff-0006">
<sup>6</sup>
</xref></contrib><contrib id="jde13956-cr-0008" contrib-type="author"><name><surname>Kawaguchi</surname><given-names>Isao</given-names></name><xref ref-type="aff" rid="jde13956-aff-0006">
<sup>6</sup>
</xref></contrib><contrib id="jde13956-cr-0009" contrib-type="author"><name><surname>Tomochika</surname><given-names>Yukiko</given-names></name><xref ref-type="aff" rid="jde13956-aff-0006">
<sup>6</sup>
</xref></contrib><contrib id="jde13956-cr-0010" contrib-type="author"><name><surname>Kobayashi</surname><given-names>Mihoko</given-names></name><xref ref-type="aff" rid="jde13956-aff-0006">
<sup>6</sup>
</xref></contrib><contrib id="jde13956-cr-0011" contrib-type="author"><name><surname>Tallman</surname><given-names>Anna M.</given-names></name><xref ref-type="aff" rid="jde13956-aff-0007">
<sup>7</sup>
</xref></contrib><contrib id="jde13956-cr-0012" contrib-type="author"><name><surname>Papp</surname><given-names>Kim A.</given-names></name><xref ref-type="aff" rid="jde13956-aff-0008">
<sup>8</sup>
</xref></contrib></contrib-group><aff id="jde13956-aff-0001">
<label><sup>1</sup></label>
<institution>Sapporo Skin Clinic</institution>
<named-content content-type="city">Sapporo</named-content>
<country country="JP">Japan</country>
</aff><aff id="jde13956-aff-0002">
<label><sup>2</sup></label>
<named-content content-type="organisation-division">Division of Dermatology</named-content>
<institution>Kobe University</institution>
<named-content content-type="city">Kobe</named-content>
<country country="JP">Japan</country>
</aff><aff id="jde13956-aff-0003">
<label><sup>3</sup></label>
<named-content content-type="organisation-division">Division of Dermatology</named-content>
<institution>Tokyo Yamate Medical Center</institution>
<named-content content-type="city">Tokyo</named-content>
<country country="JP">Japan</country>
</aff><aff id="jde13956-aff-0004">
<label><sup>4</sup></label>
<institution>Kumamoto University</institution>
<named-content content-type="city">Kumamoto</named-content>
<country country="JP">Japan</country>
</aff><aff id="jde13956-aff-0005">
<label><sup>5</sup></label>
<institution>JR Sapporo Hospital</institution>
<named-content content-type="city">Sapporo</named-content>
<country country="JP">Japan</country>
</aff><aff id="jde13956-aff-0006">
<label><sup>6</sup></label>
<institution>Pfizer Japan Inc</institution>
<named-content content-type="city">Tokyo</named-content>
<country country="JP">Japan</country>
</aff><aff id="jde13956-aff-0007">
<label><sup>7</sup></label>
<institution>Pfizer Inc</institution>
<named-content content-type="city">New York</named-content>
<country country="US">USA</country>
</aff><aff id="jde13956-aff-0008">
<label><sup>8</sup></label>
<institution>Probity Medical Research and K. Papp Clinical Research Inc.</institution>
<named-content content-type="city">Waterloo</named-content>
<named-content content-type="country-part">Ontario</named-content>
<country country="CA">Canada</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label>Correspondence: Masatoshi Abe, M.D., Ph.D., Sapporo Skin Clinic, H&#x00026;B Plaza Building 5th Floor, 1&#x02010;1, S3 W2, Chuo&#x02010;ku, Sapporo, Hokkaido 060&#x02010;0063, Japan. Email: <email>masaabe@kojinkai.org</email></corresp></author-notes><pub-date pub-type="epub"><day>17</day><month>7</month><year>2017</year></pub-date><pub-date pub-type="ppub"><month>11</month><year>2017</year></pub-date><volume>44</volume><issue>11</issue><issue-id pub-id-type="doi">10.1111/jde.2017.44.issue-11</issue-id><fpage>1228</fpage><lpage>1237</lpage><history><date date-type="received"><day>07</day><month>2</month><year>2017</year></date><date date-type="accepted"><day>24</day><month>5</month><year>2017</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> Copyright &#x000a9; 2017 Japanese Dermatological Association <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2017 The Authors. <italic>The Journal of Dermatology</italic> published by John Wiley &#x00026; Sons Australia, Ltd on behalf of Japanese Dermatological Association.</copyright-statement><license license-type="creativeCommonsBy-nc-nd"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution&#x02010;NonCommercial&#x02010;NoDerivs</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#x02010;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:JDE-44-1228.pdf"/><abstract id="jde13956-abs-0001"><title>Abstract</title><p>Tofacitinib is an oral Janus kinase inhibitor. These post&#x02010;hoc analyses assessed tofacitinib efficacy and safety in Japanese patients with psoriasis enrolled in a 52&#x02010;week global phase 3 study. Patients received tofacitinib 5 mg, tofacitinib 10 mg or placebo twice daily (b.i.d.); placebo&#x02010;treated patients advanced to tofacitinib at week 16. Primary efficacy end&#x02010;points were the proportions of patients with 75% or more reduction from baseline Psoriasis Area and Severity Index (<styled-content style="fixed-case">PASI</styled-content>&#x02010;75) and Physician's Global Assessment (<styled-content style="fixed-case">PGA</styled-content>) of &#x0201c;clear&#x0201d; or &#x0201c;almost clear&#x0201d; (<styled-content style="fixed-case">PGA</styled-content> response) at week 16. Other end&#x02010;points included: Itch Severity Item (<styled-content style="fixed-case">ISI</styled-content>), Dermatology Life Quality Index (<styled-content style="fixed-case">DLQI</styled-content>) score and Nail Psoriasis Severity Index (<styled-content style="fixed-case">NAPSI</styled-content>). Adverse events (AEs) were recorded throughout the study. Overall, 58 Japanese patients were included in this analysis (tofacitinib 5 mg b.i.d., <italic>n</italic> = 22; 10 mg b.i.d., <italic>n</italic> = 24; placebo, <italic>n</italic> = 12); 29 completed the study. At week 16, significantly more patients receiving tofacitinib 5 and 10 mg <styled-content style="fixed-case">b.i.d.</styled-content> versus placebo achieved <styled-content style="fixed-case">PASI</styled-content>&#x02010;75 (50% and 75% vs 0%, <italic>P</italic> &#x0003c; 0.01) and <styled-content style="fixed-case">PGA</styled-content> response (59% and 75% vs 0%, <italic>P</italic> &#x0003c; 0.001). Substantial improvements in <styled-content style="fixed-case">ISI</styled-content>,<styled-content style="fixed-case"> DLQI</styled-content> and <styled-content style="fixed-case">NAPSI</styled-content> score were observed with both tofacitinib doses. Over 52 weeks, similar rates of AEs were reported across treatment groups; one serious <styled-content style="fixed-case">AE</styled-content> occurred with tofacitinib 10 mg b.i.d. Herpes zoster occurred in three patients receiving tofacitinib 10 mg b.i.d. No deaths, serious infections, malignancies or gastrointestinal perforations were reported. Results were generally consistent with global analysis, suggesting sustained efficacy and a manageable safety profile, with increased herpes zoster incidence, of tofacitinib in Japanese patients with psoriasis.</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="jde13956-kwd-0001">Janus kinase inhibitor</kwd><kwd id="jde13956-kwd-0002">Japanese</kwd><kwd id="jde13956-kwd-0003">oral medicine</kwd><kwd id="jde13956-kwd-0004">plaque psoriasis</kwd><kwd id="jde13956-kwd-0005">tofacitinib</kwd></kwd-group><funding-group><award-group><funding-source>Pfizer Inc</funding-source></award-group></funding-group><counts><fig-count count="3"/><table-count count="2"/><page-count count="10"/><word-count count="7285"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>jde13956</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>November 2017</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:5.2.6 mode:remove_FC converted:21.11.2017</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group id="jde13956-ntgp-0101"><fn id="jde13956-note-1001"><p>[The copyright line for this article was changed on 16 August 2017 after original online publication.]</p></fn></fn-group></notes></front><body><sec id="jde13956-sec-0001"><title>Introduction</title><p>Psoriasis is a chronic, systemic, inflammatory disease. The most common form is plaque psoriasis, which accounts for approximately 90% of all cases.<xref rid="jde13956-bib-0001" ref-type="ref">1</xref> Psoriasis is associated with an increased incidence of chronic comorbid conditions, and psoriasis patients are at higher risk of hypertension, type 2 diabetes and cardiovascular mortality than the general population.<xref rid="jde13956-bib-0002" ref-type="ref">2</xref>, <xref rid="jde13956-bib-0003" ref-type="ref">3</xref>, <xref rid="jde13956-bib-0004" ref-type="ref">4</xref>, <xref rid="jde13956-bib-0005" ref-type="ref">5</xref> The effect of psoriasis on the patient includes psychosocial as well as physical manifestations, and can result in stigmatization, anxiety and depression, and affect interpersonal relationships.<xref rid="jde13956-bib-0006" ref-type="ref">6</xref>, <xref rid="jde13956-bib-0007" ref-type="ref">7</xref>
</p><p>The prevalence of psoriasis in the Japanese population has been reported to be 0.34%.<xref rid="jde13956-bib-0008" ref-type="ref">8</xref> Although this is lower than reported in other regions, which range from 1% in the USA to 8.5% in Norway,<xref rid="jde13956-bib-0009" ref-type="ref">9</xref> there are currently more than 400 000 Japanese patients with psoriasis.<xref rid="jde13956-bib-0008" ref-type="ref">8</xref> Given the prevalence, together with the consequences of the disease, psoriasis represents a substantial health issue in Japan.</p><p>In Japan, therapies currently approved for treatment of psoriasis include topical corticosteroids and vitamin D<sub>3</sub>, phototherapy, the oral systemic agents etretinate and cyclosporin and the injectable/infusible biologics infliximab, adalimumab, ustekinumab, secukinumab, brodalumab and ixekizumab; methotrexate is not available as a treatment option for psoriasis in Japan.<xref rid="jde13956-bib-0010" ref-type="ref">10</xref>, <xref rid="jde13956-bib-0011" ref-type="ref">11</xref>, <xref rid="jde13956-bib-0012" ref-type="ref">12</xref>, <xref rid="jde13956-bib-0013" ref-type="ref">13</xref> Topical therapies have limited effectiveness, particularly in moderate to severe disease, and are also considered inconvenient by many patients.<xref rid="jde13956-bib-0014" ref-type="ref">14</xref>, <xref rid="jde13956-bib-0015" ref-type="ref">15</xref> The effectiveness and convenience of phototherapy have also been reported to be lower than many systemic treatments.<xref rid="jde13956-bib-0014" ref-type="ref">14</xref>, <xref rid="jde13956-bib-0015" ref-type="ref">15</xref> Side&#x02010;effects, including renal failure and hypertension, limit the long&#x02010;term use of cyclosporin.<xref rid="jde13956-bib-0016" ref-type="ref">16</xref> Although biologics have a high level of therapeutic effect,<xref rid="jde13956-bib-0010" ref-type="ref">10</xref> use of some biologic agents has been associated with an increased risk of serious infections.<xref rid="jde13956-bib-0017" ref-type="ref">17</xref> In addition, some biologics can also lose efficacy over time due to the development of anti&#x02010;drug antibodies,<xref rid="jde13956-bib-0018" ref-type="ref">18</xref> and the requirement for parenteral administration may be an issue for some patients.<xref rid="jde13956-bib-0019" ref-type="ref">19</xref> Because of these limitations, there remains an unmet need for safe and effective oral therapies with unique mechanisms of action for treatment of psoriasis.</p><p>Tofacitinib is an oral Janus kinase (JAK) inhibitor. The efficacy and safety of tofacitinib 5 and 10 mg twice daily (b.i.d.) in patients with moderate to severe chronic plaque psoriasis has been demonstrated in global phase 3 trials<xref rid="jde13956-bib-0020" ref-type="ref">20</xref>, <xref rid="jde13956-bib-0021" ref-type="ref">21</xref>, <xref rid="jde13956-bib-0022" ref-type="ref">22</xref>, <xref rid="jde13956-bib-0023" ref-type="ref">23</xref> of up to 56 weeks&#x02019; duration, and in a long&#x02010;term extension (LTE) study with efficacy end&#x02010;points reported through 24 months and safety reported over 33 months of exposure.<xref rid="jde13956-bib-0023" ref-type="ref">23</xref> The efficacy and safety of tofacitinib has also been studied in several other immune&#x02010;mediated inflammatory diseases, including rheumatoid arthritis,<xref rid="jde13956-bib-0024" ref-type="ref">24</xref>, <xref rid="jde13956-bib-0025" ref-type="ref">25</xref>, <xref rid="jde13956-bib-0026" ref-type="ref">26</xref>, <xref rid="jde13956-bib-0027" ref-type="ref">27</xref>, <xref rid="jde13956-bib-0028" ref-type="ref">28</xref>, <xref rid="jde13956-bib-0029" ref-type="ref">29</xref> psoriatic arthritis (NCT01877668, NCT01882439, NCT01976364), ankylosing spondylitis,<xref rid="jde13956-bib-0030" ref-type="ref">30</xref> Crohn's disease<xref rid="jde13956-bib-0031" ref-type="ref">31</xref> (NCT01393626, NCT01393899, NCT01470599) and ulcerative colitis.<xref rid="jde13956-bib-0032" ref-type="ref">32</xref>, <xref rid="jde13956-bib-0033" ref-type="ref">33</xref>
</p><p>The phase 3 OPT Pivotal 1 study in psoriasis included sites in Japan; here, we report the results of post&#x02010;hoc analyses of data for the Japanese patients enrolled in OPT Pivotal 1. The objective of these analyses was to describe the efficacy, safety and tolerability of tofacitinib over 52 weeks in Japanese patients with chronic moderate to severe plaque psoriasis.</p></sec><sec id="jde13956-sec-0002"><title>Methods</title><sec id="jde13956-sec-0003"><title>Study design</title><p>Post&#x02010;hoc analyses were conducted using data from Japanese patients enrolled in an international, randomized, double&#x02010;blind, placebo&#x02010;controlled phase 3 study, OPT Pivotal 1 (NCT01276639).<xref rid="jde13956-bib-0022" ref-type="ref">22</xref> Patients were randomized 2:2:1 to treatment with tofacitinib 5 mg b.i.d., tofacitinib 10 mg b.i.d., or placebo b.i.d. Placebo&#x02010;treated patients were re&#x02010;randomized at week 16 to tofacitinib 5 mg b.i.d. or 10 mg b.i.d. At week 28, patients who had not achieved either 75% or more reduction from baseline in the Psoriasis Area and Severity Index (PASI&#x02010;75) or a Physician's Global Assessment of &#x0201c;clear&#x0201d; or &#x0201c;almost clear&#x0201d; (PGA response) discontinued study treatment. Tofacitinib treatment was continued up to week 52 for all patients remaining in the study. Eligible patients could enroll in an open&#x02010;label LTE study, otherwise a follow&#x02010;up visit was performed 2&#x02013;4 weeks after the patient's last dose of study medication.</p><p>The study was conducted in compliance with the Declaration of Helsinki, the Good Clinical Practice Guidelines established by the International Conference on Harmonisation, and local country regulations relevant to the use of new therapeutic agents. The final protocol, all amendments and informed consent documentation were reviewed and approved by the institutional review boards and/or the independent ethics committees of the investigational centers. Patients provided written, informed consent.</p></sec><sec id="jde13956-sec-0004"><title>Patients</title><p>Full inclusion and exclusion criteria for the OPT Pivotal 1 study have been described previously.<xref rid="jde13956-bib-0022" ref-type="ref">22</xref> Briefly, patients were aged 18 years or older, with a diagnosis of plaque&#x02010;type psoriasis 12 months or more prior to study entry, a PASI score of 12 or more, a PGA score of 3 (moderate) or 4 (severe), and 10% or more affected body surface area at baseline. Concomitant use of phototherapy, topical therapy or systemic treatments other than study medication was not allowed. Patients were excluded if they had non&#x02010;plaque forms of psoriasis or drug&#x02010;induced psoriasis; a recent systemic or local infection; evidence of active, latent or inadequately treated <italic>Mycobacterium tuberculosis</italic> infection; or a known malignancy or history of malignancies (except for adequately treated or excised basal/squamous cell carcinoma or cervical carcinoma <italic>in situ</italic>).</p></sec><sec id="jde13956-sec-0005"><title>Assessments and outcomes</title><sec id="jde13956-sec-0006"><title>Efficacy</title><p>The primary efficacy end&#x02010;points were the proportions of patients achieving PASI&#x02010;75 and PGA responses at week 16. Other end&#x02010;points included: Itch Severity Item (ISI) score, Dermatology Life Quality Index (DLQI) score and Nail Psoriasis Severity Index (NAPSI) score; and the proportions of patients achieving 90% or more reduction from baseline PASI score (PASI&#x02010;90), at least 75% reduction from baseline NAPSI score (NAPSI&#x02010;75), a score of 1 or less on the DLQI (indicating psoriasis has no effect on the patient's life),<xref rid="jde13956-bib-0034" ref-type="ref">34</xref> and a score of 1 or less on the ISI (indicating &#x0201c;little or no itch&#x0201d;).<xref rid="jde13956-bib-0035" ref-type="ref">35</xref> All end&#x02010;points were assessed at baseline and at weeks 2, 4, 8, 12, 16, 20, 28, 40 and 52, with the exception of NAPSI, which was assessed at baseline, and weeks 8, 16, 20, 28, 40 and 52.</p></sec><sec id="jde13956-sec-0007"><title>Safety</title><p>Safety end&#x02010;points included the incidence of adverse events (AEs), serious AEs, discontinuations due to AEs, and deaths. AEs of special interest, including serious infection events (defined as infections requiring parenteral antimicrobial therapy or hospitalization for treatment, or meeting other criteria requiring classification as a serious AE), herpes zoster infection (HZ), gastrointestinal perforations, major adverse cardiovascular events (MACE) and malignancies were reported. Cardiovascular events, opportunistic infections and hepatic events were adjudicated by an independent, external committee of experts. Changes in clinical laboratory parameters were assessed.</p></sec></sec><sec id="jde13956-sec-0008"><title>Statistical analyses</title><p>Post&#x02010;hoc efficacy analyses were performed on the full analysis set of Japanese patients, which comprised all randomized patients who received one or more dose of study drug. Safety analyses were performed on the safety analysis set of Japanese patients, which comprised all patients who received one or more dose of study drug.</p><p>For the primary end&#x02010;points, PASI&#x02010;75 and PGA responses at week 16, statistical comparisons of the differences between treatment groups were evaluated using Barnard's test. There was no adjustment for multiple comparisons as these were post&#x02010;hoc efficacy analyses. Non&#x02010;responder imputation (NRI) was applied to missing data. For other end&#x02010;points, descriptive statistics are presented for patients receiving tofacitinib 5 mg b.i.d., tofacitinib 10 mg b.i.d. and placebo.</p></sec></sec><sec id="jde13956-sec-0009"><title>Results</title><sec id="jde13956-sec-0010"><title>Patients</title><p>The OPT Pivotal 1 study included 900 patients in the full analysis set, of whom 58 (6.4%) were Japanese and were included in these post&#x02010;hoc analyses. Twenty&#x02010;two Japanese patients were randomized to receive tofacitinib 5 mg b.i.d., 24 to receive tofacitinib 10 mg b.i.d. and 12 to receive placebo. Only two Japanese patients randomized to receive placebo continued in the study after week 16; both were re&#x02010;randomized to receive tofacitinib 5 mg b.i.d.</p><p>In total, 29 Japanese patients completed the study and 29 discontinued. During weeks 0&#x02013;16, two patients receiving tofacitinib 5 mg b.i.d. (9%) and four receiving placebo (33%) discontinued due to lack of efficacy; a further six patients receiving tofacitinib 5 mg b.i.d. and three receiving tofacitinib 10 mg b.i.d. discontinued for this reason between weeks 16 and 52. A total of 14 patients discontinued due to AEs.</p><p>Demographics and baseline characteristics of Japanese patients were similar across treatment groups, although four patients (16.7%) in the tofacitinib 10 mg b.i.d. group reported a medical history of psoriatic arthritis, compared with one (8.3%) in the placebo group and none in the tofacitinib 5 mg b.i.d. group (Table <xref rid="jde13956-tbl-0001" ref-type="table-wrap">1</xref>).</p><table-wrap id="jde13956-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Baseline demographic and disease characteristics (FAS)</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1"/><th align="center" valign="top" rowspan="1" colspan="1">Tofacitinib 5 mg b.i.d. (<italic>N</italic> = 22)</th><th align="center" valign="top" rowspan="1" colspan="1">Tofacitinib 10 mg b.i.d. (<italic>N</italic> = 24)</th><th align="center" valign="top" rowspan="1" colspan="1">Placebo (<italic>N</italic> = 12)</th><th align="center" valign="top" rowspan="1" colspan="1">Total (<italic>N</italic> = 58)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Median age, years (Q1, Q3)</td><td align="char" char=" " rowspan="1" colspan="1">47.5 (41.0, 58.0)</td><td align="char" char=" " rowspan="1" colspan="1">47.5 (37.0, 58.0)</td><td align="char" char=" " rowspan="1" colspan="1">51.5 (43.0, 59.0)</td><td align="char" char=" " rowspan="1" colspan="1">50.0 (40.0, 58.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Male, <italic>n</italic> (%)</td><td align="char" char=" " rowspan="1" colspan="1">18 (81.8)</td><td align="char" char=" " rowspan="1" colspan="1">20 (83.3)</td><td align="char" char=" " rowspan="1" colspan="1">10 (83.3)</td><td align="char" char=" " rowspan="1" colspan="1">48 (82.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">Median weight, kg (Q1, Q3)</td><td align="char" char=" " rowspan="1" colspan="1">71.6 (61.0, 81.4)</td><td align="char" char=" " rowspan="1" colspan="1">68.5 (62.8, 77.4)</td><td align="char" char=" " rowspan="1" colspan="1">70.0 (57.5, 77.5)</td><td align="char" char=" " rowspan="1" colspan="1">70.0 (61.0, 79.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">Median BMI, kg/m<sup>2</sup> (Q1, Q3)</td><td align="char" char=" " rowspan="1" colspan="1">24.6 (22.7, 27.9)</td><td align="char" char=" " rowspan="1" colspan="1">24.6 (23.1, 27.6)</td><td align="char" char=" " rowspan="1" colspan="1">26.5 (22.0, 28.8)</td><td align="char" char=" " rowspan="1" colspan="1">25.1 (22.8, 28.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">Current smoker, <italic>n</italic> (%)</td><td align="char" char=" " rowspan="1" colspan="1">13 (59.1)</td><td align="char" char=" " rowspan="1" colspan="1">13 (54.2)</td><td align="char" char=" " rowspan="1" colspan="1">8 (66.7)</td><td align="char" char=" " rowspan="1" colspan="1">34 (58.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">Median psoriasis duration, years (Q1, Q3)</td><td align="char" char=" " rowspan="1" colspan="1">10.2 (6.0, 17.0)</td><td align="char" char=" " rowspan="1" colspan="1">9.6 (4.0, 19.0)</td><td align="char" char=" " rowspan="1" colspan="1">11.9 (9.0, 19.0)</td><td align="char" char=" " rowspan="1" colspan="1">10.3 (6.0, 17.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Median PASI score (Q1, Q3)</td><td align="char" char=" " rowspan="1" colspan="1">25.2 (20.4, 38.6)</td><td align="char" char=" " rowspan="1" colspan="1">22.4 (17.6, 30.6)</td><td align="char" char=" " rowspan="1" colspan="1">31.1 (18.8, 37.5)</td><td align="char" char=" " rowspan="1" colspan="1">22.8 (19.5, 36.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">Median BSA, % (Q1, Q3)</td><td align="char" char=" " rowspan="1" colspan="1">38.5 (31.0, 60.0)</td><td align="char" char=" " rowspan="1" colspan="1">35.0 (27.5, 53.0)</td><td align="char" char=" " rowspan="1" colspan="1">44.3 (24.8, 57.0)</td><td align="char" char=" " rowspan="1" colspan="1">37.0 (28.0, 57.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">PGA moderate, <italic>n</italic> (%)</td><td align="char" char=" " rowspan="1" colspan="1">19 (86.4)</td><td align="char" char=" " rowspan="1" colspan="1">23 (95.8)</td><td align="char" char=" " rowspan="1" colspan="1">11 (91.7)</td><td align="char" char=" " rowspan="1" colspan="1">53 (91.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">PGA severe, <italic>n</italic> (%)</td><td align="char" char=" " rowspan="1" colspan="1">3 (13.6)</td><td align="char" char=" " rowspan="1" colspan="1">1 (4.2)</td><td align="char" char=" " rowspan="1" colspan="1">1 (8.3)</td><td align="char" char=" " rowspan="1" colspan="1">5 (8.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">Median DLQI (Q1, Q3)</td><td align="char" char=" " rowspan="1" colspan="1">8.5 (5.0, 15.0)</td><td align="char" char=" " rowspan="1" colspan="1">5.5 (3.5, 8.0)</td><td align="char" char=" " rowspan="1" colspan="1">13.0 (5.5, 15.0)</td><td align="char" char=" " rowspan="1" colspan="1">8.0 (4.0, 12.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Psoriatic arthritis, <italic>n</italic> (%)</td><td align="char" char=" " rowspan="1" colspan="1">0 (0)</td><td align="char" char=" " rowspan="1" colspan="1">4 (16.7)</td><td align="char" char=" " rowspan="1" colspan="1">1 (8.3)</td><td align="char" char=" " rowspan="1" colspan="1">5 (8.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">Nail psoriasis, <italic>n</italic> (%)</td><td align="char" char=" " rowspan="1" colspan="1">16 (72.7)</td><td align="char" char=" " rowspan="1" colspan="1">20 (83.3)</td><td align="char" char=" " rowspan="1" colspan="1">10 (83.3)</td><td align="char" char=" " rowspan="1" colspan="1">46 (79.3)</td></tr></tbody></table><table-wrap-foot><fn id="jde13956-note-0001"><p>BMI, body mass index; BSA, body surface area affected by psoriasis; DLQI, Dermatology Life Quality Index; FAS, full analysis set; ISI, Itch Severity Item; NAPSI, Nail Psoriasis Severity Index; PASI, Psoriasis Area and Severity Index; PGA, Physician's Global Assessment; Q, quartile.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap></sec><sec id="jde13956-sec-0011"><title>Efficacy</title><p>A significantly greater proportion of patients achieved PASI&#x02010;75 at week 16 with tofacitinib 5 mg b.i.d. (11/22, 50%; <italic>P</italic> &#x0003c; 0.01) and tofacitinib 10 mg b.i.d. (18/24, 75%; <italic>P</italic> &#x0003c; 0.0001) versus placebo (0/12) (Fig. <xref rid="jde13956-fig-0001" ref-type="fig">1</xref>a). The proportions of patients achieving PGA response at week 16 were also significantly greater with tofacitinib 5 mg b.i.d. (13/22, 59.1%; <italic>P</italic> &#x0003c; 0.001) and tofacitinib 10 mg b.i.d. (18/24, 75.0%; <italic>P</italic> &#x0003c; 0.0001) versus placebo (0/12; Fig. <xref rid="jde13956-fig-0001" ref-type="fig">1</xref>b). PASI&#x02010;75 and PGA responses were generally sustained to week 52 (Fig. <xref rid="jde13956-fig-0001" ref-type="fig">1</xref>). At week 52, 45.5% and 66.7% of patients receiving tofacitinib 5 and 10 mg b.i.d., respectively, achieved PASI&#x02010;75, and 40.9% and 62.5% of patients achieved a PGA response. For the two patients who advanced from placebo to tofacitinib 5 mg b.i.d. at week 16, both achieved PASI&#x02010;75 and PGA response at all subsequent time points up to week 52.</p><fig fig-type="Figure" xml:lang="en" id="jde13956-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Proportion of patients achieving (a) PASI&#x02010;75 and (b) <styled-content style="fixed-case">PGA</styled-content> response through week 52 (<styled-content style="fixed-case">FAS</styled-content>,<styled-content style="fixed-case"> NRI</styled-content>). *<italic>P</italic> &#x0003c; 0.01; **<italic>P</italic> &#x0003c; 0.001; ***<italic>P</italic> &#x0003c; 0.0001 vs placebo, Barnard's test. Patients initially assigned to placebo moved to active treatment at week 16; only two patients advanced from placebo (to tofacitinib 5 mg b.i.d.), both achieved <styled-content style="fixed-case">PASI</styled-content>&#x02010;75 and <styled-content style="fixed-case">PGA</styled-content> response at all subsequent time points, data are not shown for weeks 20&#x02013;52 for these patients. At week 28, patients who did not achieve <styled-content style="fixed-case">PASI</styled-content>&#x02010;75 or <styled-content style="fixed-case">PGA</styled-content> response were withdrawn from the study. Eligible patients could enroll in an open&#x02010;label <styled-content style="fixed-case">LTE</styled-content> study; otherwise, a follow&#x02010;up visit was performed 2&#x02013;4 weeks after the patient's last dose of study medication. <styled-content style="fixed-case">CI</styled-content>, confidence interval; <styled-content style="fixed-case">FAS</styled-content>, full analysis set; <styled-content style="fixed-case">LTE</styled-content>, long&#x02010;term extension; <styled-content style="fixed-case">NRI</styled-content>, non&#x02010;responder imputation; <styled-content style="fixed-case">PASI</styled-content>, Psoriasis Area and Severity Index; <styled-content style="fixed-case">PASI</styled-content>&#x02010;75, 75% or more reduction from baseline in <styled-content style="fixed-case">PASI</styled-content> score; <styled-content style="fixed-case">PGA</styled-content>, Physician's Global Assessment; <styled-content style="fixed-case">PGA</styled-content> response, &#x0201c;clear&#x0201d; or &#x0201c;almost clear&#x0201d;.</p></caption><graphic id="nlm-graphic-1" xlink:href="JDE-44-1228-g001"/></fig><p>Numerically greater proportions of patients achieved PASI&#x02010;90 at week 16 with tofacitinib 5 mg b.i.d. (18.2%) and tofacitinib 10 mg b.i.d. (66.7%) versus placebo (0%), based on NRI. PASI&#x02010;90 responses were generally sustained to week 52 for patients who received tofacitinib 5 mg b.i.d. (27.3%) and tofacitinib 10 mg b.i.d. (50.0%).</p><p>There was a substantial improvement in pruritus by week 16 with both tofacitinib doses (Fig. <xref rid="jde13956-fig-0002" ref-type="fig">2</xref>a). At week 16, mean decreases from baseline in ISI were &#x02212;4.2 with tofacitinib 5 mg b.i.d. and &#x02212;3.7 with tofacitinib 10 mg b.i.d., versus &#x02212;0.1 with placebo. Improvements in ISI were generally maintained through week 52 with both tofacitinib doses (Fig. <xref rid="jde13956-fig-0002" ref-type="fig">2</xref>a). At week 16, based on NRI, the proportions of patients achieving ISI of 1 or less were 50.0% (11/22) and 72.7% (16/22) for the tofacitinib 5 mg and 10 mg b.i.d. doses, respectively, versus 8.3% (1/12) for placebo.</p><fig fig-type="Figure" xml:lang="en" id="jde13956-fig-0002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Change from baseline in (a) <styled-content style="fixed-case">ISI</styled-content> and (b) <styled-content style="fixed-case">DLQI</styled-content>, and (c) percent change from baseline in <styled-content style="fixed-case">NAPSI</styled-content> over 52 weeks (<styled-content style="fixed-case">FAS</styled-content>, observed cases). Patients initially assigned to placebo moved to active treatment at week 16; only two patients advanced from placebo (to tofacitinib 5 mg b.i.d.), data are not shown for weeks 20&#x02013;52 for these patients. At week 28, patients who did not achieve <styled-content style="fixed-case">PASI</styled-content>&#x02010;75 or <styled-content style="fixed-case">PGA</styled-content> response were withdrawn from the study. Eligible patients could enroll in an open&#x02010;label <styled-content style="fixed-case">LTE</styled-content> study; otherwise, a follow&#x02010;up visit was performed 2&#x02013;4 weeks after the patient's last dose of study medication. <styled-content style="fixed-case">DLQI</styled-content>, Dermatology Life Quality Index; <styled-content style="fixed-case">FAS</styled-content>, full analysis set; <styled-content style="fixed-case">ISI</styled-content>, Itch Severity Item; <styled-content style="fixed-case">LTE</styled-content>, long&#x02010;term extension; <styled-content style="fixed-case">NAPSI</styled-content>, Nail Psoriasis Severity Index; <styled-content style="fixed-case">PASI</styled-content>&#x02010;75, 75% or more reduction from baseline in <styled-content style="fixed-case">PASI</styled-content> score; <styled-content style="fixed-case">PGA</styled-content>, Physician's Global Assessment; <styled-content style="fixed-case">SE</styled-content>, standard error.</p></caption><graphic id="nlm-graphic-3" xlink:href="JDE-44-1228-g002"/></fig><p>At week 16, there was also a substantial decrease in DLQI score, indicating improvement in health&#x02010;related quality of life (HRQoL), with both tofacitinib 5 mg (&#x02212;8.2) and 10 mg (&#x02212;4.7) b.i.d., compared with an increase in mean DLQI score in patients receiving placebo (6.0; Fig. <xref rid="jde13956-fig-0002" ref-type="fig">2</xref>b). Improvement in DLQI with tofacitinib versus placebo was seen as early as week 2, with decreases in DLQI score of 2.9 and 3.4 with tofacitinib 5 and 10 mg b.i.d., respectively, at this time, versus 0.2 with placebo. Improvements in DLQI were maintained through week 52 with both tofacitinib doses (Fig. <xref rid="jde13956-fig-0002" ref-type="fig">2</xref>b). At week 16, based on NRI, the proportions of patients achieving DLQI of 1 or less were 38.1% (8/21) and 54.2% (13/24) with tofacitinib 5 and 10 mg b.i.d., respectively, versus 0% (0/11) for placebo.</p><p>Greater reductions from baseline in NAPSI score were observed at week 16 with both tofacitinib 5 mg (&#x02212;18.4%) and 10 mg (&#x02212;37.2%) b.i.d. versus placebo (50.0%; Fig. <xref rid="jde13956-fig-0002" ref-type="fig">2</xref>c). NAPSI scores continued to decrease through week 52 with both tofacitinib dose groups (Fig. <xref rid="jde13956-fig-0002" ref-type="fig">2</xref>c). At week 16, of those patients with nail psoriasis at baseline, NAPSI&#x02010;75 was achieved by 4/21 (19.1%) patients who received tofacitinib 10 mg b.i.d., and 1/11 (9.1%) patients who received placebo, based on NRI. None of the 18 patients with nail psoriasis who received tofacitinib 5 mg b.i.d. achieved NAPSI&#x02010;75 at week 16. By week 52, 4/18 (22.2%) and 10/21 (47.6%) patients who received tofacitinib 5 and 10 mg b.i.d., respectively, achieved NAPSI&#x02010;75.</p></sec><sec id="jde13956-sec-0012"><title>Safety</title><p>The percentage of patients experiencing AEs during the 16&#x02010;week placebo&#x02010;controlled period ranged from 77% with tofacitinib 5 mg b.i.d. to 92% with placebo across treatment groups (Table <xref rid="jde13956-tbl-0002" ref-type="table-wrap">2</xref>). Up to week 16, AEs resulting in discontinuation occurred in four patients receiving tofacitinib 5 mg b.i.d., four receiving tofacitinib 10 mg b.i.d. and six receiving placebo. No further discontinuations due to AEs occurred between weeks 16 and 52 (Table <xref rid="jde13956-tbl-0002" ref-type="table-wrap">2</xref>). Up to week 16, most AEs (96.9%) were mild to moderate; four severe AEs were reported, all in placebo&#x02010;treated patients. No severe AEs were reported after week 16. Nasopharyngitis was the most commonly reported AE throughout the 52 weeks&#x02019; observation. In addition, there was a relatively high rate of AEs related to laboratory parameter abnormalities (Table <xref rid="jde13956-tbl-0002" ref-type="table-wrap">2</xref>).</p><table-wrap id="jde13956-tbl-0002" xml:lang="en" orientation="portrait" position="float"><label>Table 2</label><caption><p>Adverse events through week 52 (safety analysis set)</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="top" colspan="1"/><th align="center" colspan="3" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Weeks 0&#x02013;16</th><th align="center" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Weeks 0&#x02013;52</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Tofacitinib 5 mg b.i.d. (<italic>N</italic> = 22)</th><th align="center" valign="top" rowspan="1" colspan="1">Tofacitinib 10 mg b.i.d. (<italic>N</italic> = 24)</th><th align="center" valign="top" rowspan="1" colspan="1">Placebo (<italic>N</italic> = 12)</th><th align="center" valign="top" rowspan="1" colspan="1">Tofacitinib 5 mg b.i.d. (<italic>N</italic> = 22)</th><th align="center" valign="top" rowspan="1" colspan="1">Tofacitinib 10 mg b.i.d. (<italic>N</italic> = 24)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Patients with AEs, <italic>n</italic> (%)</td><td align="char" char=" " rowspan="1" colspan="1">17 (77.3)</td><td align="char" char=" " rowspan="1" colspan="1">21 (87.5)</td><td align="char" char=" " rowspan="1" colspan="1">11 (91.7)</td><td align="char" char=" " rowspan="1" colspan="1">20 (90.9)</td><td align="char" char=" " rowspan="1" colspan="1">23 (95.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">Patients with SAEs, <italic>n</italic> (%)</td><td align="char" char=" " rowspan="1" colspan="1">0 (0.0)</td><td align="char" char=" " rowspan="1" colspan="1">1 (4.2)</td><td align="char" char=" " rowspan="1" colspan="1">0 (0.0)</td><td align="char" char=" " rowspan="1" colspan="1">0 (0.0)</td><td align="char" char=" " rowspan="1" colspan="1">1 (4.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">Patients discontinued due to AEs, <italic>n</italic> (%)</td><td align="char" char=" " rowspan="1" colspan="1">4 (18.2)</td><td align="char" char=" " rowspan="1" colspan="1">4 (16.7)</td><td align="char" char=" " rowspan="1" colspan="1">6 (50.0)</td><td align="char" char=" " rowspan="1" colspan="1">4 (18.2)</td><td align="char" char=" " rowspan="1" colspan="1">4 (16.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">Patients with SIEs, <italic>n</italic> (%)</td><td align="char" char=" " rowspan="1" colspan="1">0 (0.0)</td><td align="char" char=" " rowspan="1" colspan="1">0 (0.0)</td><td align="char" char=" " rowspan="1" colspan="1">0 (0.0)</td><td align="char" char=" " rowspan="1" colspan="1">0 (0.0)</td><td align="char" char=" " rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Patients with HZ, <italic>n</italic> (%)</td><td align="char" char=" " rowspan="1" colspan="1">0 (0.0)</td><td align="char" char=" " rowspan="1" colspan="1">1 (4.2)</td><td align="char" char=" " rowspan="1" colspan="1">0 (0.0)</td><td align="char" char=" " rowspan="1" colspan="1">0 (0.0)</td><td align="char" char=" " rowspan="1" colspan="1">3 (12.5)</td></tr><tr><td align="left" colspan="6" rowspan="1">Most common AEs,<xref ref-type="fn" rid="jde13956-note-0002">&#x02020;</xref>
<italic>n</italic> (%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Nasopharyngitis</td><td align="char" char=" " rowspan="1" colspan="1">4 (18.2)</td><td align="char" char=" " rowspan="1" colspan="1">4 (16.7)</td><td align="char" char=" " rowspan="1" colspan="1">3 (25.0)</td><td align="char" char=" " rowspan="1" colspan="1">7 (31.8)</td><td align="char" char=" " rowspan="1" colspan="1">13 (54.2)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Blood cholesterol increased</td><td align="char" char=" " rowspan="1" colspan="1">4 (18.2)</td><td align="char" char=" " rowspan="1" colspan="1">5 (20.8)</td><td align="char" char=" " rowspan="1" colspan="1">0 (0.0)</td><td align="char" char=" " rowspan="1" colspan="1">5 (22.7)</td><td align="char" char=" " rowspan="1" colspan="1">5 (20.8)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Blood CPK increased</td><td align="char" char=" " rowspan="1" colspan="1">2 (9.1)</td><td align="char" char=" " rowspan="1" colspan="1">2 (8.3)</td><td align="char" char=" " rowspan="1" colspan="1">0 (0.0)</td><td align="char" char=" " rowspan="1" colspan="1">5 (22.7)</td><td align="char" char=" " rowspan="1" colspan="1">4 (16.7)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">&#x003b3;&#x02010;GT increased</td><td align="char" char=" " rowspan="1" colspan="1">2 (9.1)</td><td align="char" char=" " rowspan="1" colspan="1">1 (4.2)</td><td align="char" char=" " rowspan="1" colspan="1">0 (0.0)</td><td align="char" char=" " rowspan="1" colspan="1">4 (18.2)</td><td align="char" char=" " rowspan="1" colspan="1">4 (16.7)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">LDL increased</td><td align="char" char=" " rowspan="1" colspan="1">4 (18.2)</td><td align="char" char=" " rowspan="1" colspan="1">2 (8.3)</td><td align="char" char=" " rowspan="1" colspan="1">0 (0.0)</td><td align="char" char=" " rowspan="1" colspan="1">5 (22.7)</td><td align="char" char=" " rowspan="1" colspan="1">3 (12.5)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Psoriasis</td><td align="char" char=" " rowspan="1" colspan="1">4 (18.2)</td><td align="char" char=" " rowspan="1" colspan="1">1 (4.2)</td><td align="char" char=" " rowspan="1" colspan="1">8 (66.7)</td><td align="char" char=" " rowspan="1" colspan="1">5 (22.7)</td><td align="char" char=" " rowspan="1" colspan="1">1 (4.2)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Hyperlipidemia</td><td align="char" char=" " rowspan="1" colspan="1">0 (0.0)</td><td align="char" char=" " rowspan="1" colspan="1">4 (16.7)</td><td align="char" char=" " rowspan="1" colspan="1">0 (0.0)</td><td align="char" char=" " rowspan="1" colspan="1">0 (0.0)</td><td align="char" char=" " rowspan="1" colspan="1">5 (20.8)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Influenza</td><td align="char" char=" " rowspan="1" colspan="1">0 (0.0)</td><td align="char" char=" " rowspan="1" colspan="1">2 (8.3)</td><td align="char" char=" " rowspan="1" colspan="1">0 (0.0)</td><td align="char" char=" " rowspan="1" colspan="1">0 (0.0)</td><td align="char" char=" " rowspan="1" colspan="1">5 (20.8)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Back pain</td><td align="char" char=" " rowspan="1" colspan="1">1 (4.5)</td><td align="char" char=" " rowspan="1" colspan="1">1 (4.2)</td><td align="char" char=" " rowspan="1" colspan="1">1 (8.3)</td><td align="char" char=" " rowspan="1" colspan="1">3 (13.6)</td><td align="char" char=" " rowspan="1" colspan="1">1 (4.2)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Blood triglycerides increased</td><td align="char" char=" " rowspan="1" colspan="1">0 (0.0)</td><td align="char" char=" " rowspan="1" colspan="1">3 (12.5)</td><td align="char" char=" " rowspan="1" colspan="1">1 (8.3)</td><td align="char" char=" " rowspan="1" colspan="1">0 (0.0)</td><td align="char" char=" " rowspan="1" colspan="1">3 (12.5)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Gout</td><td align="char" char=" " rowspan="1" colspan="1">0 (0.0)</td><td align="char" char=" " rowspan="1" colspan="1">0 (0.0)</td><td align="char" char=" " rowspan="1" colspan="1">2 (16.7)</td><td align="char" char=" " rowspan="1" colspan="1">0 (0.0)</td><td align="char" char=" " rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Arthralgia</td><td align="char" char=" " rowspan="1" colspan="1">0 (0.0)</td><td align="char" char=" " rowspan="1" colspan="1">0 (0.0)</td><td align="char" char=" " rowspan="1" colspan="1">2 (16.7)</td><td align="char" char=" " rowspan="1" colspan="1">0 (0.0)</td><td align="char" char=" " rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">HZ</td><td align="char" char=" " rowspan="1" colspan="1">0 (0.0)</td><td align="char" char=" " rowspan="1" colspan="1">1 (4.2)</td><td align="char" char=" " rowspan="1" colspan="1">0 (0.0)</td><td align="char" char=" " rowspan="1" colspan="1">0 (0.0)</td><td align="char" char=" " rowspan="1" colspan="1">3 (12.5)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Folliculitis</td><td align="char" char=" " rowspan="1" colspan="1">0 (0.0)</td><td align="char" char=" " rowspan="1" colspan="1">0 (0.0)</td><td align="char" char=" " rowspan="1" colspan="1">0 (0.0)</td><td align="char" char=" " rowspan="1" colspan="1">0 (0.0)</td><td align="char" char=" " rowspan="1" colspan="1">3 (12.5)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Pruritus</td><td align="char" char=" " rowspan="1" colspan="1">1 (4.5)</td><td align="char" char=" " rowspan="1" colspan="1">0 (0.0)</td><td align="char" char=" " rowspan="1" colspan="1">2 (16.7)</td><td align="char" char=" " rowspan="1" colspan="1">1 (4.5)</td><td align="char" char=" " rowspan="1" colspan="1">0 (0.0)</td></tr></tbody></table><table-wrap-foot><fn id="jde13956-note-0002"><p>&#x02020;By Medical Dictionary for Regulatory Activities (MedDRA) preferred term; occurring in more than 10% of patients. AE, adverse event; CPK, creatine phosphokinase; &#x003b3;&#x02010;GT, &#x003b3;&#x02010;glutamyltransferase; HZ, herpes zoster; LDL, low&#x02010;density lipoprotein; SAE, serious adverse event; SIE, serious infection event.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><p>One serious AE was reported: a patient receiving tofacitinib 10 mg b.i.d. suffered a cerebral infarction prior to week 16, which was adjudicated as a MACE. The patient was discontinued from the study. This AE was determined by the investigator not to be related to the study drug. No deaths, serious infections, malignancies or gastrointestinal perforations were reported. Three patients experienced HZ infections; all were receiving tofacitinib 10 mg b.i.d. One case was reported in weeks 0&#x02013;16 and two in weeks 16&#x02013;52. One case was mild and two were moderate in severity. No patients were hospitalized due to HZ and no serious HZ events were reported.</p><p>Small mean increases in low&#x02010;density lipoprotein cholesterol (LDL&#x02010;C) were observed by week 4 after initiation of tofacitinib treatment, with mean levels increasing by 13.9 mg/dL from 102.6 mg/dL at baseline with tofacitinib 5 mg b.i.d., and by 18.6 mg/dL from 111.7 mg/dL at baseline with tofacitinib 10 mg b.i.d. (Fig. <xref rid="jde13956-fig-0003" ref-type="fig">3</xref>). Similar increases at week 4 were also observed in high&#x02010;density lipoprotein cholesterol (HDL&#x02010;C); mean levels increased by 9.6 mg/dL from 53.6 mg/dL at baseline with tofacitinib 5 mg b.i.d., and by 14.0 mg/dL from 54.5 mg/dL at baseline with tofacitinib 10 mg b.i.d. (Fig. <xref rid="jde13956-fig-0003" ref-type="fig">3</xref>). For both LDL&#x02010;C and HDL&#x02010;C, levels were generally stable from week 4 through week 52 (Fig. <xref rid="jde13956-fig-0003" ref-type="fig">3</xref>).</p><fig fig-type="Figure" xml:lang="en" id="jde13956-fig-0003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Change from baseline in (a) <styled-content style="fixed-case">LDL&#x02010;C</styled-content> and (b) <styled-content style="fixed-case">HDL&#x02010;C</styled-content> over 52 weeks (<styled-content style="fixed-case">FAS</styled-content>, observed cases). Patients initially assigned to placebo moved to active treatment at week 16; only two patients advanced from placebo (to tofacitinib 5 mg b.i.d.), data are not shown for weeks 20&#x02013;52 for these patients. <styled-content style="fixed-case">FAS</styled-content>, full analysis set; <styled-content style="fixed-case">HDL&#x02010;C</styled-content>, high&#x02010;density lipoprotein cholesterol; <styled-content style="fixed-case">LDL&#x02010;C</styled-content>, low&#x02010;density lipoprotein cholesterol; <styled-content style="fixed-case">SE</styled-content>, standard error.</p></caption><graphic id="nlm-graphic-5" xlink:href="JDE-44-1228-g003"/></fig><p>One patient, with a baseline lymphocyte count of 1.22 &#x000d7; 10<sup>3</sup>/mm<sup>3</sup>, receiving tofacitinib 5 mg b.i.d., had a confirmed lymphocyte count below 0.5 &#x000d7; 10<sup>3</sup>/mm<sup>3</sup> during the study. Two patients had confirmed decreased hemoglobin levels (defined as a decrease from baseline of 3 g/dL or more or hemoglobin absolute value of 7 g/dL or less) during the study. One patient receiving tofacitinib 10 mg b.i.d., with a baseline hemoglobin level of 18.6 g/dL, had values of more than 3 g/dL below baseline levels reported at each visit from day 85 onward. The second patient was receiving placebo, and had a baseline value of 14.8 g/dL. Reduction in hemoglobin of more than 3 g/dL was reported on study day 30, but returned to within 3 g/dL of the baseline value by day 57. No patients had a confirmed neutrophil count below 1.2 &#x000d7; 10<sup>3</sup>/mm<sup>3</sup> or alanine or aspartate aminotransferase levels of &#x000d7;3 or more the upper limit of normal.</p></sec></sec><sec id="jde13956-sec-0013"><title>Discussion</title><p>In these post&#x02010;hoc analyses, the efficacy and safety of tofacitinib, an oral JAK inhibitor, was analyzed in Japanese patients with moderate to severe plaque psoriasis who had participated in the phase 3 OPT Pivotal 1 study.</p><p>Significant improvement in the signs and symptoms of psoriasis with tofacitinib 5 mg and 10 mg b.i.d. compared with placebo were demonstrated, as measured by patients achieving PASI&#x02010;75 or PGA response at week 16; improvements were sustained up to 52 weeks. Numerically greater response rates were seen with tofacitinib 10 mg b.i.d. compared with 5 mg b.i.d. Improvements were seen in other efficacy outcomes, including HRQoL, pruritus and nail psoriasis. Changes were clinically meaningful; at week 16, 50% and 73% of patients receiving tofacitinib 5 and 10 mg b.i.d., respectively, achieved an ISI score of 1 or less, equating to &#x0201c;little or no itch&#x0201d;,<xref rid="jde13956-bib-0035" ref-type="ref">35</xref> and 38% and 54% of patients receiving tofacitinib 5 and 10 mg b.i.d., respectively, achieved DLQI of 1 or less, indicating psoriasis had no effect on the patient's quality of life.<xref rid="jde13956-bib-0034" ref-type="ref">34</xref>
</p><p>Efficacy was somewhat higher in Japanese patients receiving tofacitinib than the global population. The proportions of Japanese patients achieving PASI&#x02010;75 at week 16 were 50%, 75% and 0% with tofacitinib 5 mg b.i.d., tofacitinib 10 mg b.i.d. and placebo, respectively, compared with 40% (145/363), 59% (213/360) and 6% (11/177) for the global population of OPT Pivotal 1.<xref rid="jde13956-bib-0022" ref-type="ref">22</xref> At week 16, 59%, 75% and 0% of Japanese patients receiving tofacitinib 5 mg b.i.d., tofacitinib 10 mg b.i.d. and placebo, respectively, achieved PGA response; in the OPT Pivotal 1 global population, these proportions were 42% (152/363), 59% (213/360) and 9% (16/177).<xref rid="jde13956-bib-0022" ref-type="ref">22</xref> A similar trend of higher efficacy in Japanese patients compared with the global population was also reported in a randomized, double&#x02010;blind, multicenter, phase 3 study conducted in Japan.<xref rid="jde13956-bib-0036" ref-type="ref">36</xref> In this study, 63% (27/43) and 73% (32/44) of patients receiving tofacitinib 5 mg b.i.d. and 10 mg b.i.d., respectively, achieved PASI&#x02010;75, and 67% (29/43) and 68% (30/44) achieved PGA response at week 16.</p><p>Comparison of the efficacy of tofacitinib with other psoriasis treatments in Japanese patients is challenging, as only one study has directly compared tofacitinib with an active comparator (etanercept) in a head&#x02010;to&#x02010;head study; however, that study did not include sites in Japan.<xref rid="jde13956-bib-0020" ref-type="ref">20</xref> Based on indirect comparisons, tofacitinib appears to have efficacy within the range of biologic therapies in Japanese patients. For example, in a phase 2/3 study of adalimumab (80 mg loading dose followed by 40 mg every other week) in Japanese patients with psoriasis, 63% (27/43) of patients achieved PASI&#x02010;75 at week 16,<xref rid="jde13956-bib-0037" ref-type="ref">37</xref> and in a study of Japanese patients receiving infliximab (5 mg/kg at weeks 0, 2 and 6, and then every 8 weeks), 72% (26/36) and 54% (15/28) of patients achieved PASI&#x02010;75 after 10 and 50 weeks of treatment, respectively.<xref rid="jde13956-bib-0038" ref-type="ref">38</xref> In tumor necrosis factor inhibitor&#x02010;naive Japanese patients receiving ustekinumab for 16 weeks, 88% (7/8) achieved PASI&#x02010;75.<xref rid="jde13956-bib-0039" ref-type="ref">39</xref> Similarly, in a subanalysis of Japanese patients from a global study of patients with psoriasis receiving secukinumab 150 mg or 300 mg (once weekly for 4 weeks and then once every 4 weeks), PASI&#x02010;75 and PGA responses at week 12 were achieved by 86% (25/29) and 55% (16/29), respectively, of patients receiving 150 mg, and by 83% (24/29) and 55% (16/29) of those receiving 300 mg.<xref rid="jde13956-bib-0040" ref-type="ref">40</xref>
</p><p>No unexpected safety findings were observed in Japanese patients during the 52&#x02010;week treatment period; commonly reported AEs were generally consistent with studies of tofacitinib for moderate to severe plaque psoriasis in global populations<xref rid="jde13956-bib-0020" ref-type="ref">20</xref>, <xref rid="jde13956-bib-0021" ref-type="ref">21</xref>, <xref rid="jde13956-bib-0022" ref-type="ref">22</xref>, <xref rid="jde13956-bib-0023" ref-type="ref">23</xref> and in a phase 3 multicenter Japanese study.<xref rid="jde13956-bib-0036" ref-type="ref">36</xref> The proportions of patients reporting treatment&#x02010;emergent AEs, serious AEs and discontinuing due to AEs during the initial 16&#x02010;week placebo&#x02010;controlled period appeared to be somewhat higher in the Japanese than in the global population of OPT Pivotal 1,<xref rid="jde13956-bib-0022" ref-type="ref">22</xref> and higher than reported in the phase 3 study conducted in Japan;<xref rid="jde13956-bib-0036" ref-type="ref">36</xref> however, it is difficult to interpret these findings given the limited number of patients included in these post&#x02010;hoc analyses. Changes in laboratory parameters and the incidence of laboratory test abnormalities were similar to previous reports of tofacitinib in both the phase 3 global and Japanese studies.<xref rid="jde13956-bib-0022" ref-type="ref">22</xref>, <xref rid="jde13956-bib-0036" ref-type="ref">36</xref>
</p><p>In these analyses, the incidence of HZ infection over 52 weeks of treatment in patients receiving tofacitinib 10 mg b.i.d. (12.5%) was higher than in the global population (5/360, 1.4%);<xref rid="jde13956-bib-0022" ref-type="ref">22</xref> no cases were reported in Japanese patients receiving tofacitinib 5 mg b.i.d. compared with 0.8% (3/363 patients) in the global studies. In a previous phase 3 study in Japanese patients with psoriasis,<xref rid="jde13956-bib-0036" ref-type="ref">36</xref> HZ was reported in 17.0% (16/94) of patients. An increased incidence of HZ in Japanese patients compared with those from other regions has also been reported in previous studies of tofacitinib in rheumatoid arthritis<xref rid="jde13956-bib-0041" ref-type="ref">41</xref> and in psoriasis.<xref rid="jde13956-bib-0042" ref-type="ref">42</xref> However, the reason behind these regional differences is currently unclear. These findings should be considered alongside reports of an increased risk of HZ infection in patients with inflammatory disease, including psoriasis, treated with some biologics.<xref rid="jde13956-bib-0043" ref-type="ref">43</xref>, <xref rid="jde13956-bib-0044" ref-type="ref">44</xref>, <xref rid="jde13956-bib-0045" ref-type="ref">45</xref>, <xref rid="jde13956-bib-0046" ref-type="ref">46</xref>, <xref rid="jde13956-bib-0047" ref-type="ref">47</xref> Although there has been some controversy around the level of HZ risk associated with biologics for inflammatory disease,<xref rid="jde13956-bib-0044" ref-type="ref">44</xref>, <xref rid="jde13956-bib-0048" ref-type="ref">48</xref>, <xref rid="jde13956-bib-0049" ref-type="ref">49</xref>, <xref rid="jde13956-bib-0050" ref-type="ref">50</xref> there appears to be strong evidence suggesting an increased risk with monoclonal tumor necrosis factor&#x02010;&#x003b1; inhibitors,<xref rid="jde13956-bib-0046" ref-type="ref">46</xref>, <xref rid="jde13956-bib-0047" ref-type="ref">47</xref> and particularly with infliximab.<xref rid="jde13956-bib-0043" ref-type="ref">43</xref> However, an analysis of US health plan data suggested that the HZ risk associated with tofacitinib in rheumatoid arthritis patients was approximately double that with biologics.<xref rid="jde13956-bib-0051" ref-type="ref">51</xref> An increased incidence of HZ infection in Japanese patients receiving biologic treatment for psoriasis, above that observed in the general population, has also been reported.<xref rid="jde13956-bib-0052" ref-type="ref">52</xref>
</p><p>Limitations of these post&#x02010;hoc analyses include the relatively small sample size of the Japanese subpopulation; 58 Japanese patients enrolled, and only 29 completed the study. This high level of discontinuation leads to some difficulties in interpreting findings. The discontinuation rate is much higher than that seen in the phase 3 study in Japanese patients with psoriasis<xref rid="jde13956-bib-0036" ref-type="ref">36</xref> and in the global population in the OPT Pivotal 1 study;<xref rid="jde13956-bib-0022" ref-type="ref">22</xref> there is no clear reason for this difference. In addition, the requirement for discontinuation of non&#x02010;responders at week 28, although necessary to ensure appropriate patient care, does limit the conclusions that can be drawn with regard to efficacy between weeks 28 and 52.</p><p>In conclusion, oral tofacitinib demonstrated efficacy that appeared to be sustained over 52 weeks with a manageable safety profile in Japanese patients with moderate to severe chronic plaque psoriasis; results were generally consistent with the global studies.</p></sec><sec id="jde13956-sec-0015"><title>Conflict of Interest</title><p>H. T. has received speaker fees from AbbVie, Janssen Pharmaceutical, Maruho, Mitsubishi Tanabe Pharma and Novartis Pharma. K. P. is a consultant, speaker and investigator for AbbVie, Akros, Amgen, Anacor, Astellas, Baxalta, Baxter, Boehringer Ingelheim, BMS, Celgene, Dermira, Eli Lilly, Galderma, GSK, Janssen, Leo, MSD, Merck Serono, Mitsubishi, Mylan, Novartis, Pfizer Inc, Stiefel, Sun Pharma, Takeda, UCB and Valeant. M. N., N. I., I. K., Y. T., M. K. and A. M. T. are shareholders and employees of Pfizer Inc.</p></sec></body><back><ack id="jde13956-sec-0014"><title>Acknowledgments</title><p>The authors thank the patients, investigators, and study teams involved in the OPT Pivotal 1 study. This study was funded by Pfizer Inc. Medical writing support under direction from the authors was provided by Carole Evans, Ph.D., on behalf of Complete Medical Communications, and was funded by Pfizer Inc.</p></ack><ref-list content-type="cited-references" id="jde13956-bibl-0001"><title>References</title><ref id="jde13956-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="jde13956-cit-0001">
<string-name>
<surname>Boehncke</surname>
<given-names>WH</given-names>
</string-name>, <string-name>
<surname>Schon</surname>
<given-names>MP</given-names>
</string-name>. <article-title>Psoriasis</article-title>. <source>Lancet</source>
<year>2015</year>; <volume>386</volume>: <fpage>983</fpage>&#x02013;<lpage>994</lpage>.<pub-id pub-id-type="pmid">26025581</pub-id></mixed-citation></ref><ref id="jde13956-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="jde13956-cit-0002">
<string-name>
<surname>Mehta</surname>
<given-names>NN</given-names>
</string-name>, <string-name>
<surname>Azfar</surname>
<given-names>RS</given-names>
</string-name>, <string-name>
<surname>Shin</surname>
<given-names>DB</given-names>
</string-name>, <string-name>
<surname>Neimann</surname>
<given-names>AL</given-names>
</string-name>, <string-name>
<surname>Troxel</surname>
<given-names>AB</given-names>
</string-name>, <string-name>
<surname>Gelfand</surname>
<given-names>JM</given-names>
</string-name>. <article-title>Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database</article-title>. <source>Eur Heart J</source>
<year>2010</year>; <volume>31</volume>: <fpage>1000</fpage>&#x02013;<lpage>1006</lpage>.<pub-id pub-id-type="pmid">20037179</pub-id></mixed-citation></ref><ref id="jde13956-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="jde13956-cit-0003">
<string-name>
<surname>Solomon</surname>
<given-names>DH</given-names>
</string-name>, <string-name>
<surname>Love</surname>
<given-names>TJ</given-names>
</string-name>, <string-name>
<surname>Canning</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Schneeweiss</surname>
<given-names>S</given-names>
</string-name>. <article-title>Risk of diabetes among patients with rheumatoid arthritis, psoriatic arthritis and psoriasis</article-title>. <source>Ann Rheum Dis</source>
<year>2010</year>; <volume>69</volume>: <fpage>2114</fpage>&#x02013;<lpage>2117</lpage>.<pub-id pub-id-type="pmid">20584807</pub-id></mixed-citation></ref><ref id="jde13956-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="jde13956-cit-0004">
<string-name>
<surname>Cohen</surname>
<given-names>AD</given-names>
</string-name>, <string-name>
<surname>Dreiher</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Shapiro</surname>
<given-names>Y</given-names>
</string-name>
<italic>et al</italic>
<article-title>Psoriasis and diabetes: a population&#x02010;based cross&#x02010;sectional study</article-title>. <source>J Eur Acad Dermatol Venereol</source>
<year>2008</year>; <volume>22</volume>: <fpage>585</fpage>&#x02013;<lpage>589</lpage>.<pub-id pub-id-type="pmid">18331320</pub-id></mixed-citation></ref><ref id="jde13956-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="jde13956-cit-0005">
<string-name>
<surname>Shapiro</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Cohen</surname>
<given-names>AD</given-names>
</string-name>, <string-name>
<surname>Weitzman</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Tal</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>David</surname>
<given-names>M</given-names>
</string-name>. <article-title>Psoriasis and cardiovascular risk factors: a case&#x02010;control study on inpatients comparing psoriasis to dermatitis</article-title>. <source>J Am Acad Dermatol</source>
<year>2012</year>; <volume>66</volume>: <fpage>252</fpage>&#x02013;<lpage>258</lpage>.<pub-id pub-id-type="pmid">21742411</pub-id></mixed-citation></ref><ref id="jde13956-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="jde13956-cit-0006">
<string-name>
<surname>Feldman</surname>
<given-names>SR</given-names>
</string-name>, <string-name>
<surname>Malakouti</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Koo</surname>
<given-names>JY</given-names>
</string-name>. <article-title>Social impact of the burden of psoriasis: effects on patients and practice</article-title>. <source>Dermatol Online J</source>
<year>2014</year>; <volume>20</volume>.</mixed-citation></ref><ref id="jde13956-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="jde13956-cit-0007">
<string-name>
<surname>Dowlatshahi</surname>
<given-names>EA</given-names>
</string-name>, <string-name>
<surname>Wakkee</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Arends</surname>
<given-names>LR</given-names>
</string-name>, <string-name>
<surname>Nijsten</surname>
<given-names>T</given-names>
</string-name>. <article-title>The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: a systematic review and meta&#x02010;analysis</article-title>. <source>J Invest Dermatol</source>
<year>2014</year>; <volume>134</volume>: <fpage>1542</fpage>&#x02013;<lpage>1551</lpage>.<pub-id pub-id-type="pmid">24284419</pub-id></mixed-citation></ref><ref id="jde13956-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="jde13956-cit-0008">
<string-name>
<surname>Kubota</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Kamijima</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Sato</surname>
<given-names>T</given-names>
</string-name>
<italic>et al</italic>
<article-title>Epidemiology of psoriasis and palmoplantar pustulosis: a nationwide study using the Japanese national claims database</article-title>. <source>BMJ Open</source>
<year>2015</year>; <volume>5</volume>: <fpage>e006450</fpage>.</mixed-citation></ref><ref id="jde13956-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="jde13956-cit-0009">
<string-name>
<surname>Parisi</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Symmons</surname>
<given-names>DP</given-names>
</string-name>, <string-name>
<surname>Griffiths</surname>
<given-names>CE</given-names>
</string-name>, <string-name>
<surname>Ashcroft</surname>
<given-names>DM</given-names>
</string-name>. <article-title>Global epidemiology of psoriasis: a systematic review of incidence and prevalence</article-title>. <source>J Invest Dermatol</source>
<year>2013</year>; <volume>133</volume>: <fpage>377</fpage>&#x02013;<lpage>385</lpage>.<pub-id pub-id-type="pmid">23014338</pub-id></mixed-citation></ref><ref id="jde13956-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="jde13956-cit-0010">
<string-name>
<surname>Ohtsuki</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Terui</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Ozawa</surname>
<given-names>A</given-names>
</string-name>
<italic>et al</italic>
<article-title>Japanese guidance for use of biologics for psoriasis (the 2013 version)</article-title>. <source>J Dermatol</source>
<year>2013</year>; <volume>40</volume>: <fpage>683</fpage>&#x02013;<lpage>695</lpage>.<pub-id pub-id-type="pmid">24033880</pub-id></mixed-citation></ref><ref id="jde13956-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="jde13956-cit-0011">
<string-name>
<surname>Greig</surname>
<given-names>SL</given-names>
</string-name>. <article-title>Brodalumab: first global approval</article-title>. <source>Drugs</source>
<year>2016</year>; <volume>76</volume>: <fpage>1403</fpage>&#x02013;<lpage>1412</lpage>.<pub-id pub-id-type="pmid">27577550</pub-id></mixed-citation></ref><ref id="jde13956-bib-0012"><label>12</label><mixed-citation publication-type="miscellaneous" id="jde13956-cit-0012">
<collab collab-type="authors">Pharmaceuticals and Medical Devices Agency</collab>
. <article-title>Report on the Deliberation Results &#x02010; Cosentyx</article-title>. [Cited 17 Jan 2017] Available from URL: <ext-link ext-link-type="uri" xlink:href="http://www.pmda.go.jp/files/000210413.pdf#page=33">http://www.pmda.go.jp/files/000210413.pdf#page=33</ext-link>. Last updated 2014.</mixed-citation></ref><ref id="jde13956-bib-0013"><label>13</label><mixed-citation publication-type="miscellaneous" id="jde13956-cit-0013">
<collab collab-type="authors">Pharmaceuticals and Medical Devices Agency</collab>
. <article-title>Approved products list (new drug: 5/2016)</article-title>. [Cited 21 Dec 2016] Available from URL: <ext-link ext-link-type="uri" xlink:href="https://www.pmda.go.jp/files/000215608.pdf">https://www.pmda.go.jp/files/000215608.pdf</ext-link>. Last updated 2016.</mixed-citation></ref><ref id="jde13956-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="jde13956-cit-0014">
<string-name>
<surname>Callis Duffin</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Yeung</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Takeshita</surname>
<given-names>J</given-names>
</string-name>
<italic>et al</italic>
<article-title>Patient satisfaction with treatments for moderate&#x02010;to&#x02010;severe plaque psoriasis in clinical practice</article-title>. <source>Br J Dermatol</source>
<year>2014</year>; <volume>170</volume>: <fpage>672</fpage>&#x02013;<lpage>680</lpage>.<pub-id pub-id-type="pmid">24266717</pub-id></mixed-citation></ref><ref id="jde13956-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="jde13956-cit-0015">
<string-name>
<surname>van Cranenburgh</surname>
<given-names>OD</given-names>
</string-name>, <string-name>
<surname>de Korte</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Sprangers</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>de Rie</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Smets</surname>
<given-names>EM</given-names>
</string-name>. <article-title>Satisfaction with treatment among patients with psoriasis: a web&#x02010;based survey study</article-title>. <source>Br J Dermatol</source>
<year>2013</year>; <volume>169</volume>: <fpage>398</fpage>&#x02013;<lpage>405</lpage>.<pub-id pub-id-type="pmid">23565643</pub-id></mixed-citation></ref><ref id="jde13956-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="jde13956-cit-0016">
<string-name>
<surname>Pathirana</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Ormerod</surname>
<given-names>AD</given-names>
</string-name>, <string-name>
<surname>Saiag</surname>
<given-names>P</given-names>
</string-name>
<italic>et al</italic>
<article-title>European S3&#x02010;guidelines on the systemic treatment of psoriasis vulgaris</article-title>. <source>J Eur Acad Dermatol Venereol</source>
<year>2009</year>; <volume>23</volume> (<issue>Suppl 2</issue>): <fpage>1</fpage>&#x02013;<lpage>70</lpage>.</mixed-citation></ref><ref id="jde13956-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="jde13956-cit-0017">
<string-name>
<surname>Kalb</surname>
<given-names>RE</given-names>
</string-name>, <string-name>
<surname>Fiorentino</surname>
<given-names>DF</given-names>
</string-name>, <string-name>
<surname>Lebwohl</surname>
<given-names>MG</given-names>
</string-name>
<italic>et al</italic>
<article-title>Risk of serious infection with biologic and systemic treatment of psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)</article-title>. <source>JAMA Dermatol</source>
<year>2015</year>; <volume>151</volume>: <fpage>961</fpage>&#x02013;<lpage>969</lpage>.<pub-id pub-id-type="pmid">25970800</pub-id></mixed-citation></ref><ref id="jde13956-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="jde13956-cit-0018">
<string-name>
<surname>Vincent</surname>
<given-names>FB</given-names>
</string-name>, <string-name>
<surname>Morand</surname>
<given-names>EF</given-names>
</string-name>, <string-name>
<surname>Murphy</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Mackay</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Mariette</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Marcelli</surname>
<given-names>C</given-names>
</string-name>. <article-title>Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)&#x02010;specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective</article-title>. <source>Ann Rheum Dis</source>
<year>2013</year>; <volume>72</volume>: <fpage>165</fpage>&#x02013;<lpage>178</lpage>.<pub-id pub-id-type="pmid">23178294</pub-id></mixed-citation></ref><ref id="jde13956-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="jde13956-cit-0019">
<string-name>
<surname>Lebwohl</surname>
<given-names>MG</given-names>
</string-name>, <string-name>
<surname>Bachelez</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Barker</surname>
<given-names>J</given-names>
</string-name>
<italic>et al</italic>
<article-title>Patient perspectives in the management of psoriasis: results from the population&#x02010;based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey</article-title>. <source>J Am Acad Dermatol</source>
<year>2014</year>; <volume>70</volume>: <fpage>871</fpage>&#x02013;<lpage>881</lpage>.<pub-id pub-id-type="pmid">24576585</pub-id></mixed-citation></ref><ref id="jde13956-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="jde13956-cit-0020">
<string-name>
<surname>Bachelez</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>van de Kerkhof</surname>
<given-names>PC</given-names>
</string-name>, <string-name>
<surname>Strohal</surname>
<given-names>R</given-names>
</string-name>
<italic>et al</italic>
<article-title>Tofacitinib versus etanercept or placebo in moderate&#x02010;to&#x02010;severe chronic plaque psoriasis: a phase 3 randomised non&#x02010;inferiority trial</article-title>. <source>Lancet</source>
<year>2015</year>; <volume>386</volume>: <fpage>552</fpage>&#x02013;<lpage>561</lpage>.<pub-id pub-id-type="pmid">26051365</pub-id></mixed-citation></ref><ref id="jde13956-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="jde13956-cit-0021">
<string-name>
<surname>Bissonnette</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Iversen</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Sofen</surname>
<given-names>H</given-names>
</string-name>
<italic>et al</italic>
<article-title>Tofacitinib withdrawal and retreatment in moderate&#x02010;to&#x02010;severe chronic plaque psoriasis: a randomized controlled trial</article-title>. <source>Br J Dermatol</source>
<year>2015</year>; <volume>172</volume>: <fpage>1395</fpage>&#x02013;<lpage>1406</lpage>.<pub-id pub-id-type="pmid">25418186</pub-id></mixed-citation></ref><ref id="jde13956-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="jde13956-cit-0022">
<string-name>
<surname>Papp</surname>
<given-names>KA</given-names>
</string-name>, <string-name>
<surname>Menter</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Abe</surname>
<given-names>M</given-names>
</string-name>
<italic>et al</italic>
<article-title>Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two, randomized, placebo&#x02010;controlled, phase III trials</article-title>. <source>Br J Dermatol</source>
<year>2015</year>; <volume>173</volume>: <fpage>949</fpage>&#x02013;<lpage>961</lpage>.<pub-id pub-id-type="pmid">26149717</pub-id></mixed-citation></ref><ref id="jde13956-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="jde13956-cit-0023">
<string-name>
<surname>Papp</surname>
<given-names>KA</given-names>
</string-name>, <string-name>
<surname>Krueger</surname>
<given-names>JG</given-names>
</string-name>, <string-name>
<surname>Feldman</surname>
<given-names>SR</given-names>
</string-name>
<italic>et al</italic>
<article-title>Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: long&#x02010;term efficacy and safety results from 2 randomized phase&#x02010;III studies and 1 open&#x02010;label long&#x02010;term extension study</article-title>. <source>J Am Acad Dermatol</source>
<year>2016</year>; <volume>74</volume>: <fpage>841</fpage>&#x02013;<lpage>850</lpage>.<pub-id pub-id-type="pmid">26899199</pub-id></mixed-citation></ref><ref id="jde13956-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="jde13956-cit-0024">
<string-name>
<surname>Burmester</surname>
<given-names>GR</given-names>
</string-name>, <string-name>
<surname>Blanco</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Charles&#x02010;Schoeman</surname>
<given-names>C</given-names>
</string-name>
<italic>et al</italic>
<article-title>Tofacitinib (CP&#x02010;690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial</article-title>. <source>Lancet</source>
<year>2013</year>; <volume>381</volume>: <fpage>451</fpage>&#x02013;<lpage>460</lpage>.<pub-id pub-id-type="pmid">23294500</pub-id></mixed-citation></ref><ref id="jde13956-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="jde13956-cit-0025">
<string-name>
<surname>Fleischmann</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Kremer</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Cush</surname>
<given-names>J</given-names>
</string-name>
<italic>et al</italic>
<article-title>Placebo&#x02010;controlled trial of tofacitinib monotherapy in rheumatoid arthritis</article-title>. <source>N Engl J Med</source>
<year>2012</year>; <volume>367</volume>: <fpage>495</fpage>&#x02013;<lpage>507</lpage>.<pub-id pub-id-type="pmid">22873530</pub-id></mixed-citation></ref><ref id="jde13956-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="jde13956-cit-0026">
<string-name>
<surname>Lee</surname>
<given-names>EB</given-names>
</string-name>, <string-name>
<surname>Fleischmann</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Hall</surname>
<given-names>S</given-names>
</string-name>
<italic>et al</italic>
<article-title>Tofacitinib versus methotrexate in rheumatoid arthritis</article-title>. <source>N Engl J Med</source>
<year>2014</year>; <volume>370</volume>: <fpage>2377</fpage>&#x02013;<lpage>2386</lpage>.<pub-id pub-id-type="pmid">24941177</pub-id></mixed-citation></ref><ref id="jde13956-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="jde13956-cit-0027">
<string-name>
<surname>Kremer</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>ZG</given-names>
</string-name>, <string-name>
<surname>Hall</surname>
<given-names>S</given-names>
</string-name>
<italic>et al</italic>
<article-title>Tofacitinib in combination with nonbiologic disease&#x02010;modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial</article-title>. <source>Ann Intern Med</source>
<year>2013</year>; <volume>159</volume>: <fpage>253</fpage>&#x02013;<lpage>261</lpage>.<pub-id pub-id-type="pmid">24026258</pub-id></mixed-citation></ref><ref id="jde13956-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="jde13956-cit-0028">
<string-name>
<surname>van der Heijde</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Tanaka</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Fleischmann</surname>
<given-names>R</given-names>
</string-name>
<italic>et al</italic>
<article-title>Tofacitinib (CP&#x02010;690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve&#x02010;month data from a twenty&#x02010;four&#x02010;month phase III randomized radiographic study</article-title>. <source>Arthritis Rheum</source>
<year>2013</year>; <volume>65</volume>: <fpage>559</fpage>&#x02013;<lpage>570</lpage>.<pub-id pub-id-type="pmid">23348607</pub-id></mixed-citation></ref><ref id="jde13956-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="jde13956-cit-0029">
<string-name>
<surname>van Vollenhoven</surname>
<given-names>RF</given-names>
</string-name>, <string-name>
<surname>Fleischmann</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Cohen</surname>
<given-names>S</given-names>
</string-name>
<italic>et al</italic>
<article-title>Tofacitinib or adalimumab versus placebo in rheumatoid arthritis</article-title>. <source>N Engl J Med</source>
<year>2012</year>; <volume>367</volume>: <fpage>508</fpage>&#x02013;<lpage>519</lpage>.<pub-id pub-id-type="pmid">22873531</pub-id></mixed-citation></ref><ref id="jde13956-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="jde13956-cit-0030">
<string-name>
<surname>van der Heijde</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Deodhar</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Wei</surname>
<given-names>JC</given-names>
</string-name>
<italic>et al</italic>
<article-title>Tofacitinib in patients with ankylosing spondylitis: a Phase II, 16&#x02010;week, randomised, placebo&#x02010;controlled, dose&#x02010;ranging study</article-title>. <source>Ann Rheum Dis</source>
<year>2017</year>; <volume>76</volume>: <fpage>1340</fpage>&#x02013;<lpage>1347</lpage>.<pub-id pub-id-type="pmid">28130206</pub-id></mixed-citation></ref><ref id="jde13956-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="jde13956-cit-0031">
<string-name>
<surname>Sandborn</surname>
<given-names>WJ</given-names>
</string-name>, <string-name>
<surname>Ghosh</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Panes</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Vranic</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Niezychowski</surname>
<given-names>W</given-names>
</string-name>. <article-title>A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn's disease</article-title>. <source>Clin Gastroenterol Hepatol</source>
<year>2014</year>; <volume>12</volume>: <fpage>1485</fpage>&#x02013;<lpage>1493</lpage>.<pub-id pub-id-type="pmid">24480677</pub-id></mixed-citation></ref><ref id="jde13956-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="jde13956-cit-0032">
<string-name>
<surname>Sandborn</surname>
<given-names>WJ</given-names>
</string-name>, <string-name>
<surname>Ghosh</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Panes</surname>
<given-names>J</given-names>
</string-name>
<italic>et al</italic>
<article-title>Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis</article-title>. <source>N Engl J Med</source>
<year>2012</year>; <volume>367</volume>: <fpage>616</fpage>&#x02013;<lpage>624</lpage>.<pub-id pub-id-type="pmid">22894574</pub-id></mixed-citation></ref><ref id="jde13956-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="jde13956-cit-0033">
<string-name>
<surname>Sandborn</surname>
<given-names>WJ</given-names>
</string-name>, <string-name>
<surname>Sands</surname>
<given-names>BE</given-names>
</string-name>, <string-name>
<surname>D'Haens</surname>
<given-names>G</given-names>
</string-name>
<italic>et al</italic>
<article-title>Efficacy and safety of oral tofacitinib as induction therapy in patients with moderate&#x02010;to&#x02010;severe ulcerative colitis: results from 2 phase 3 randomised controlled trials</article-title>. <source>J Crohns Colitis</source>
<year>2016</year>; <volume>10</volume>: <fpage>S1</fpage>, OP19 (abstract).</mixed-citation></ref><ref id="jde13956-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="jde13956-cit-0034">
<string-name>
<surname>Hongbo</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Thomas</surname>
<given-names>CL</given-names>
</string-name>, <string-name>
<surname>Harrison</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Salek</surname>
<given-names>MS</given-names>
</string-name>, <string-name>
<surname>Finlay</surname>
<given-names>AY</given-names>
</string-name>. <article-title>Translating the science of quality of life into practice: what do dermatology life quality index scores mean?</article-title>
<source>J Invest Dermatol</source>
<year>2005</year>; <volume>125</volume>: <fpage>659</fpage>&#x02013;<lpage>664</lpage>.<pub-id pub-id-type="pmid">16185263</pub-id></mixed-citation></ref><ref id="jde13956-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="jde13956-cit-0035">
<string-name>
<surname>Valenzuela</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Paul</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Mallbris</surname>
<given-names>L</given-names>
</string-name>
<italic>et al</italic>
<article-title>Tofacitinib versus etanercept or placebo in patients with moderate to severe chronic plaque psoriasis: patient&#x02010;reported outcomes from a Phase 3 study</article-title>. <source>J Eur Acad Dermatol Venereol</source>
<year>2016</year>; <volume>30</volume>: <fpage>1753</fpage>&#x02013;<lpage>1759</lpage>.<pub-id pub-id-type="pmid">27271195</pub-id></mixed-citation></ref><ref id="jde13956-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="jde13956-cit-0036">
<string-name>
<surname>Asahina</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Etoh</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Igarashi</surname>
<given-names>A</given-names>
</string-name>, <italic>et al</italic>
<article-title>Oral tofacitinib efficacy, safety and tolerability in Japanese patients with moderate to severe plaque psoriasis and psoriatic arthritis: a randomized, double&#x02010;blind, phase 3 study</article-title>. <source>J Dermatol</source>
<year>2016</year>; <volume>43</volume>: <fpage>869</fpage>&#x02013;<lpage>880</lpage>.<pub-id pub-id-type="pmid">26875540</pub-id></mixed-citation></ref><ref id="jde13956-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="jde13956-cit-0037">
<string-name>
<surname>Asahina</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Nakagawa</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Etoh</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Ohtsuki</surname>
<given-names>M</given-names>
</string-name>. <article-title>Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: efficacy and safety results from a Phase II/III randomized controlled study</article-title>. <source>J Dermatol</source>
<year>2010</year>; <volume>37</volume>: <fpage>299</fpage>&#x02013;<lpage>310</lpage>.<pub-id pub-id-type="pmid">20507398</pub-id></mixed-citation></ref><ref id="jde13956-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="jde13956-cit-0038">
<string-name>
<surname>Torii</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Nakagawa</surname>
<given-names>H</given-names>
</string-name>. <article-title>Long&#x02010;term study of infliximab in Japanese patients with plaque psoriasis, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma</article-title>. <source>J Dermatol</source>
<year>2011</year>; <volume>38</volume>: <fpage>321</fpage>&#x02013;<lpage>334</lpage>.<pub-id pub-id-type="pmid">21544940</pub-id></mixed-citation></ref><ref id="jde13956-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="jde13956-cit-0039">
<string-name>
<surname>Takahashi</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Noda</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Taniguchi</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Adachi</surname>
<given-names>M</given-names>
</string-name>. <article-title>Efficacy comparison of ustekinumab between anti&#x02010;tumor necrosis factor&#x02010;alpha drug&#x02010;naive and anti&#x02010;tumor necrosis factor&#x02010;alpha drug&#x02010;resistant Japanese psoriasis cases</article-title>. <source>Int J Dermatol</source>
<year>2015</year>; <volume>54</volume>: <fpage>1194</fpage>&#x02013;<lpage>1198</lpage>.<pub-id pub-id-type="pmid">26016819</pub-id></mixed-citation></ref><ref id="jde13956-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="jde13956-cit-0040">
<string-name>
<surname>Ohtsuki</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Morita</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Abe</surname>
<given-names>M</given-names>
</string-name>
<italic>et al</italic>
<article-title>Secukinumab efficacy and safety in Japanese patients with moderate&#x02010;to&#x02010;severe plaque psoriasis: subanalysis from ERASURE, a randomized, placebo&#x02010;controlled, phase 3 study</article-title>. <source>J Dermatol</source>
<year>2014</year>; <volume>41</volume>: <fpage>1039</fpage>&#x02013;<lpage>1046</lpage>.<pub-id pub-id-type="pmid">25354738</pub-id></mixed-citation></ref><ref id="jde13956-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="jde13956-cit-0041">
<string-name>
<surname>Winthrop</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Yamanaka</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Valdez</surname>
<given-names>H</given-names>
</string-name>
<italic>et al</italic>
<article-title>Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis</article-title>. <source>Arthritis Rheumatol</source>
<year>2014</year>; <volume>66</volume>: <fpage>2675</fpage>&#x02013;<lpage>2684</lpage>.<pub-id pub-id-type="pmid">24943354</pub-id></mixed-citation></ref><ref id="jde13956-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="jde13956-cit-0042">
<string-name>
<surname>Valdez</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Winthrop</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Lebwohl</surname>
<given-names>M</given-names>
</string-name>
<italic>et al</italic>
<article-title>Herpes zoster and tofacitinib therapy in patients with psoriasis</article-title>. <source>J Invest Dermatol</source>
<year>2015</year>; <volume>135</volume>:P040 (abstract).</mixed-citation></ref><ref id="jde13956-bib-0043"><label>43</label><mixed-citation publication-type="journal" id="jde13956-cit-0043">
<string-name>
<surname>Adelzadeh</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Jourabchi</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Wu</surname>
<given-names>JJ</given-names>
</string-name>. <article-title>The risk of herpes zoster during biological therapy for psoriasis and other inflammatory conditions</article-title>. <source>J Eur Acad Dermatol Venereol</source>
<year>2014</year>; <volume>28</volume>: <fpage>846</fpage>&#x02013;<lpage>852</lpage>.<pub-id pub-id-type="pmid">25081573</pub-id></mixed-citation></ref><ref id="jde13956-bib-0044"><label>44</label><mixed-citation publication-type="journal" id="jde13956-cit-0044">
<string-name>
<surname>Shalom</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Zisman</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Bitterman</surname>
<given-names>H</given-names>
</string-name>
<italic>et al</italic>
<article-title>Systemic therapy for psoriasis and the risk of herpes zoster: a 500000 person&#x02010;year study</article-title>. <source>JAMA Dermatol</source>
<year>2015</year>; <volume>151</volume>: <fpage>533</fpage>&#x02013;<lpage>538</lpage>.<pub-id pub-id-type="pmid">25797026</pub-id></mixed-citation></ref><ref id="jde13956-bib-0045"><label>45</label><mixed-citation publication-type="journal" id="jde13956-cit-0045">
<string-name>
<surname>Dreiher</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Kresch</surname>
<given-names>FS</given-names>
</string-name>, <string-name>
<surname>Comaneshter</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Cohen</surname>
<given-names>AD</given-names>
</string-name>. <article-title>Risk of herpes zoster in patients with psoriasis treated with biologic drugs</article-title>. <source>J Eur Acad Dermatol Venereol</source>
<year>2012</year>; <volume>26</volume>: <fpage>1127</fpage>&#x02013;<lpage>1132</lpage>.<pub-id pub-id-type="pmid">21923837</pub-id></mixed-citation></ref><ref id="jde13956-bib-0046"><label>46</label><mixed-citation publication-type="journal" id="jde13956-cit-0046">
<string-name>
<surname>Segan</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Staples</surname>
<given-names>MP</given-names>
</string-name>, <string-name>
<surname>March</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Lassere</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Chakravarty</surname>
<given-names>EF</given-names>
</string-name>, <string-name>
<surname>Buchbinder</surname>
<given-names>R</given-names>
</string-name>. <article-title>Risk factors for herpes zoster in rheumatoid arthritis patients: the role of tumour necrosis factor&#x02010;alpha inhibitors</article-title>. <source>Intern Med J</source>
<year>2015</year>; <volume>45</volume>: <fpage>310</fpage>&#x02013;<lpage>318</lpage>.<pub-id pub-id-type="pmid">25565419</pub-id></mixed-citation></ref><ref id="jde13956-bib-0047"><label>47</label><mixed-citation publication-type="journal" id="jde13956-cit-0047">
<string-name>
<surname>Che</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Lukas</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Morel</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Combe</surname>
<given-names>B</given-names>
</string-name>. <article-title>Risk of herpes/herpes zoster during anti&#x02010;tumor necrosis factor therapy in patients with rheumatoid arthritis. Systematic review and meta&#x02010;analysis</article-title>. <source>Joint Bone Spine</source>
<year>2014</year>; <volume>81</volume>: <fpage>215</fpage>&#x02013;<lpage>221</lpage>.<pub-id pub-id-type="pmid">23932722</pub-id></mixed-citation></ref><ref id="jde13956-bib-0048"><label>48</label><mixed-citation publication-type="journal" id="jde13956-cit-0048">
<string-name>
<surname>Pappas</surname>
<given-names>DA</given-names>
</string-name>, <string-name>
<surname>Hooper</surname>
<given-names>MM</given-names>
</string-name>, <string-name>
<surname>Kremer</surname>
<given-names>JM</given-names>
</string-name>
<italic>et al</italic>
<article-title>Herpes zoster reactivation in patients with rheumatoid arthritis: analysis of disease characteristics and disease&#x02010;modifying anti&#x02010;rheumatic drugs</article-title>. <source>Arthritis Care Res (Hoboken)</source>
<year>2015</year>; <volume>67</volume>: <fpage>1671</fpage>&#x02013;<lpage>1678</lpage>.<pub-id pub-id-type="pmid">26018115</pub-id></mixed-citation></ref><ref id="jde13956-bib-0049"><label>49</label><mixed-citation publication-type="journal" id="jde13956-cit-0049">
<string-name>
<surname>Marra</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Lo</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Kalashnikov</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Richardson</surname>
<given-names>K</given-names>
</string-name>. <article-title>Risk of herpes zoster in individuals on biologics, disease&#x02010;modifying antirheumatic drugs, and/or corticosteroids for autoimmune diseases: a systematic review and meta&#x02010;analysis</article-title>. <source>Open Forum Infect Dis</source>
<year>2016</year>; <volume>3</volume>: <fpage>ofw205</fpage>.<pub-id pub-id-type="pmid">27942537</pub-id></mixed-citation></ref><ref id="jde13956-bib-0050"><label>50</label><mixed-citation publication-type="journal" id="jde13956-cit-0050">
<string-name>
<surname>Zisman</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Bitterman</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Shalom</surname>
<given-names>G</given-names>
</string-name>
<italic>et al</italic>
<article-title>Psoriatic arthritis treatment and the risk of herpes zoster</article-title>. <source>Ann Rheum Dis</source>
<year>2016</year>; <volume>75</volume>: <fpage>131</fpage>&#x02013;<lpage>135</lpage>.<pub-id pub-id-type="pmid">25261573</pub-id></mixed-citation></ref><ref id="jde13956-bib-0051"><label>51</label><mixed-citation publication-type="journal" id="jde13956-cit-0051">
<string-name>
<surname>Curtis</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Xie</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Yun</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Bernatsky</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Winthrop</surname>
<given-names>KL</given-names>
</string-name>. <article-title>Real&#x02010;world comparative risks of herpes virus infections in tofacitinib and biologic&#x02010;treated patients with rheumatoid arthritis</article-title>. <source>Ann Rheum Dis</source>
<year>2016</year>; <volume>75</volume>: <fpage>1843</fpage>&#x02013;<lpage>1847</lpage>.<pub-id pub-id-type="pmid">27113415</pub-id></mixed-citation></ref><ref id="jde13956-bib-0052"><label>52</label><mixed-citation publication-type="journal" id="jde13956-cit-0052">
<string-name>
<surname>Umezawa</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Fukuchi</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Ito</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Saeki</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Nakagawa</surname>
<given-names>H</given-names>
</string-name>. <article-title>Risk of herpes zoster in psoriatic patients undergoing biologic treatment</article-title>. <source>J Dermatol</source>
<year>2014</year>; <volume>41</volume>: <fpage>168</fpage>&#x02013;<lpage>170</lpage>.<pub-id pub-id-type="pmid">24433215</pub-id></mixed-citation></ref></ref-list></back></article>